Related Experiment Videos
Ciprofloxacin in meningococcal carriers.
1Medical Section, General Headquarters, Finnish Defence Forces, Helsinki.
Scandinavian Journal of Infectious Diseases. Supplementum
|January 1, 1989
Summary
Chemoprophylaxis for meningococcal disease remains crucial. Ciprofloxacin offers a single-dose solution for eradicating meningococci carriers, making it a recommended option for adults.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Meningococcal disease chemoprophylaxis is essential despite vaccination against common strains.
- Emergence of sulfonamide-resistant strains led to rifampin use, but resistance can develop.
- Rifampin resistance during short-term prophylaxis limits its suitability.
Purpose of the Study:
- To evaluate ciprofloxacin as a chemoprophylactic agent for meningococcal disease.
- To assess the efficacy of a single-dose ciprofloxacin regimen.
Main Methods:
- Review of studies investigating ciprofloxacin for meningococcal eradication.
- Analysis of ciprofloxacin's effectiveness in clearing nasopharyngeal carriers.
Main Results:
- Ciprofloxacin has demonstrated effectiveness in eradicating meningococci from carriers.
- A single dose of ciprofloxacin appears sufficient for this purpose.
Conclusions:
- Ciprofloxacin is a viable alternative for meningococcal disease chemoprophylaxis in adults.
- Single-dose ciprofloxacin shows promise for preventing meningococcal disease.